CAR-T – Page 10 – REGENHEALTHSOLUTIONS (RHS)

PIER MARIA FORNASARI
2019-09-14

University of Pennsylvania Announces Completion of Exclusive R&D Alliance With Novartis and Development of New Focused Relationship

Penn to Broaden Pathways for Development of New CAR T Cell Therapies Following a landmark, first-of-its-kind collaboration that spawned the global CAR T cell therapy industry, the University of Pennsylvania and Novartis have concluded their seven-year research and development alliance, which resulted in the world’s first approved gene therapy for cancer. They will continue to

No Comments InCAR-T

PIER MARIA FORNASARI
2019-09-12

CAR T-Cell Therapy May Be Harnessed to Treat Heart Disease

Penn study finds immunotherapy reduces cardiac fibrosis and restores heart function in mice after cardiac injury CAR T-cell therapy, a rapidly emerging form of immunotherapy using patients’ own cells to treat certain types of cancers, may be a viable treatment option for another life-threatening condition: heart disease. In a first-of-its-kind study, published today in Nature, researchers

No Comments InCAR-T

PIER MARIA FORNASARI
2019-09-12

Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56

The inhibitory receptors PD-1, Tim-3, and Lag-3 are highly expressed on tumor-infiltrating lymphocytes and compromise their antitumor activity. For efficient cancer immunotherapy, it is important to prevent chimeric antigen receptor T (CAR-T)-cell exhaustion. Here we downregulate these three checkpoint receptors simultaneously on CAR-T cells and that show the resulting PTL-CAR-T cells undergo epigenetic modifications and better control

No Comments InCAR-T

PIER MARIA FORNASARI
2019-09-10

Clinical lessons learned from the first leg of the CAR T cell journey

Chimeric antigen receptor (CAR) T cell therapy for B cell malignancies has surpassed expectations, driving an ever-expanding number of clinical trials and the first US Food and Drug Administration approvals of cell therapies for the treatment of cancer. This experience has illuminated some generalizable requirements for CAR T cell efficacy as well as the interplay

No Comments InCAR-T

PIER MARIA FORNASARI
2019-08-25

$9 million grant funds trial of CAR T-cell therapy for metastatic breast cancer

California Institute for Regenerative Medicine awarded a $9.28 million grant will support a clinical trial at City of Hope to evaluate chimeric antigen receptor T-cell therapy for patients with HER2-positive breast cancer that spread to the brain. About 20% of breast cancers are HER2-positive, and nearly half of women with this type of breast cancer develop brain

No Comments InCAR-T

PIER MARIA FORNASARI
2019-08-19

Immune Cell Bank Bets on Future CAR T Success

Source The Scientist The company Cell Vault offers to hold consumers’ T cells for later use, but scientists suggest the service would benefit very few users. new cryopreservation bank offers customers the chance to stash away their T cells for use in future cancer treatments. Using a similar model to cord blood banks, the startup

No Comments InCAR-T

PIER MARIA FORNASARI
2019-08-16

Enhancing CAR T-cell therapy through cellular imaging and radiotherapy.

Source The Lancet. Oncology, ISSN: 1474-5488, Vol: 20, Issue: 8, Page: e443-e451 Chimeric antigen receptor (CAR) T-cell therapy is one of the most remarkable advances in cancer therapy in the last several decades. More than 300 adoptive T-cell therapy trials are ongoing, which is a testament to the early success and hope engendered by this

No Comments InCAR-T

PIER MARIA FORNASARI
2019-08-16

Social value decreases with delay of CAR-T cell therapy delivery

New research has observed that the benefits of CAR-T cell immunotherapies – for the treatment of diseases such as pediatric acute lymphoblastic leukemia and diffuse large B-cell lymphoma – may be offset by their delayed delivery to patients. The social value of a therapy balances manufacturer costs and profits versus a patient’s improvement in quality-adjusted

No Comments InCAR-T

PIER MARIA FORNASARI
2019-08-09

Centers for Medicare & Medicaid Services (CMS) Make CAR T-Cell Cancer Therapy Available to Medicare Beneficiaries Nationwide

Decision ensures consistency in access to the innovative new cancer therapy, and CMS is working closely with sister agencies to monitor outcomes for patients receiving the therapy Today the Centers for Medicare & Medicaid Services (CMS), under the leadership of President Trump and Secretary Azar, finalized the decision to cover FDA-approved Chimeric Antigen Receptor T-cell, or “CAR

No Comments InCAR-T

PIER MARIA FORNASARI
2019-08-05

Car-T: the first agreement for new therapies, based on actual results, is ready. Martini (Ex Dg Aifa): “A new negotiation model that puts Italy at the forefront”

The first agreement (with Novartis) for therapies that allow to reprogram some cells of the patient (the T lymphocytes), in order to make them able, once reinfused, to recognize and target the tumors, is approved by the CPR and CTS of Aifa. Now the agreement will have to be ratified by the AIFA Board and

No Comments InCAR-T

REGENERATIVE AND PERSONALISED MEDICINE

DIGITAL HEALTHCARE

Category CAR-T

University of Pennsylvania Announces Completion of Exclusive R&D Alliance With Novartis and Development of New Focused Relationship

CAR T-Cell Therapy May Be Harnessed to Treat Heart Disease

Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56

Clinical lessons learned from the first leg of the CAR T cell journey

$9 million grant funds trial of CAR T-cell therapy for metastatic breast cancer

Immune Cell Bank Bets on Future CAR T Success

Enhancing CAR T-cell therapy through cellular imaging and radiotherapy.

Centers for Medicare & Medicaid Services (CMS) Make CAR T-Cell Cancer Therapy Available to Medicare Beneficiaries Nationwide

Car-T: the first agreement for new therapies, based on actual results, is ready. Martini (Ex Dg Aifa): “A new negotiation model that puts Italy at the forefront”